# Pfizer Inc. – Consensus ‘buy’ rating and 26.8% Upside Potential

- Link: https://www.directorstalkinterviews.com/pfizer-inc.consensus-buy-rating-and-26.8-upside-potential/4121136282
- Published: 2023-12-15T11:48:45+00:00
- Author: Charlotte Edwards

**Pfizer Inc.** which can be found using ticker (PFE) have now 20 analysts in total
covering the stock. The consensus rating is pointing to ‘buy’. The range between
the high target price and low target price is between $46.30 and $27.78 with the
average target price sitting at $33.80. Given that the stocks previous close was
at $26.66 this now indicates there is a potential upside of 26.8%. The 50 day moving
average now sits at $30.59 and the 200 moving average now moves to $35.83. The company
has a market cap of 150.53B. The current share price for the company is: $26.13 
USD

 The potential market cap would be $190,848,742,903 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of 14.28, revenue per share of $12.16
and a 2.39% return on assets.

Pfizer Inc. is a research-based biopharmaceutical company. The Company is engaged
in the discovery, development, manufacture, marketing, sale and distribution of 
biopharmaceutical products around the world. The Company operates through two segments:
Biopharma and PC1. Biopharma is engaged in the science-based biopharmaceutical business.
PC1 is its global contract development and manufacturing organization and supplier
of specialty active pharmaceutical ingredients. The Company’s primary care products
include Eliquis, Nurtec ODT/Vydura and the Premarin family; the Prevnar family, 
Nimenrix, FSME/IMMUN-TicoVac and Trumenba; Comirnaty, and Paxlovid. Its specialty
care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra,
Eucrisa/Staquis and Cibinqo; the Vyndaqel family, Oxbryta, BeneFIX and Genotropin,
and Sulperazon, Medrol, Zavicefta, Zithromax, Vfend and Panzyga. Its oncology products
include Ibrance, Xtandi, Inlyta, Retacrit, Lorbrena and Braftovi.

Share on:
